Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT06253520
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times
Summary
This early-phase trial tests a personalized treatment for adults with metastatic solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. Doctors take a person's own white blood cells, modify them in a lab to better recognize and attack cancer cells, and return them to the patient along with a vaccine to boost their effect. The goal is to see if this combination is safe and can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.